预测 KRAS 抑制的耐药性：USP21 在巨胞饮调控中的新作用。
Anticipating resistance to KRAS inhibition: a novel role for USP21 in macropinocytosis regulation.
机构信息
Henry Ford Pancreatic Cancer Center, Henry Ford Health System, Detroit, Michigan 48202, USA
出版信息
Genes Dev. 2021 Oct 1;35(19-20):1325-1326. doi: 10.1101/gad.348971.121.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. Virtually all PDAC harbors an oncogenic mutation in the KRAS gene, making it the prime target for therapy. Most previous attempts to inhibit KRAS directly have been disappointing, but recent success in targeting some KRAS mutants presages a new era in PDAC therapy. Models of PDAC have predicted that identifying KRAS inhibitor resistance mechanisms will be critical. In this issue of , Hou and colleagues (pp. 1327-1332) identify one such mechanism in which the deubiquitinase USP21 up-regulates the nutrient-scavenging process of macropinocytosis, rescuing PDAC cells from extinction.
摘要
胰腺导管腺癌 (PDAC) 是最致命的癌症之一。几乎所有 PDAC 都携带有致癌基因突变 KRAS，使其成为治疗的主要靶点。大多数直接抑制 KRAS 的先前尝试都令人失望，但最近靶向某些 KRAS 突变体的成功预示着 PDAC 治疗的新时代即将到来。PDAC 模型预测，确定 KRAS 抑制剂耐药机制将是关键。在本期 中，Hou 及其同事（第 1327-1332 页）在其中一种机制中发现了这样一种机制，去泛素化酶 USP21 上调了巨胞饮作用的营养摄取过程，使 PDAC 细胞免于灭绝。
相似文献
1
Anticipating resistance to KRAS inhibition: a novel role for USP21 in macropinocytosis regulation.
Genes Dev. 2021 Oct 1;35(19-20):1325-1326. doi: 10.1101/gad.348971.121.
2
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer.
Genes Dev. 2021 Oct 1;35(19-20):1327-1332. doi: 10.1101/gad.348787.121. Epub 2021 Sep 16.
3
Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Carcinogenesis. 2020 Mar 13;41(1):44-55. doi: 10.1093/carcin/bgz086.
4
Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.
Int J Mol Sci. 2024 Jun 6;25(11):6249. doi: 10.3390/ijms25116249.
5
Atypical KRAS Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.
Cancer Discov. 2020 Jan;10(1):104-123. doi: 10.1158/2159-8290.CD-19-1006. Epub 2019 Oct 24.
6
Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma.
Biomed Pharmacother. 2024 Aug;177:116991. doi: 10.1016/j.biopha.2024.116991. Epub 2024 Jun 21.
7
A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma.
Oncogene. 2022 Feb;41(8):1203-1215. doi: 10.1038/s41388-021-02159-9. Epub 2022 Jan 27.
8
The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients.
Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101473. doi: 10.1016/j.clinre.2020.05.021. Epub 2020 Jun 24.
9
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.
Nature. 2019 Apr;568(7752):410-414. doi: 10.1038/s41586-019-1062-1. Epub 2019 Mar 27.
10
MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Biomed Pharmacother. 2019 Nov;119:109424. doi: 10.1016/j.biopha.2019.109424. Epub 2019 Sep 12.
引用本文的文献
1
KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Int J Mol Sci. 2023 May 26;24(11):9313. doi: 10.3390/ijms24119313.
2
USP21 Promotes the Progression of Nasopharyngeal Carcinoma by Regulating FOXM1.
Stem Cells Int. 2023 Feb 11;2023:9196583. doi: 10.1155/2023/9196583. eCollection 2023.
3
Insights Into the Properties, Biological Functions, and Regulation of USP21.
Front Pharmacol. 2022 Jun 30;13:944089. doi: 10.3389/fphar.2022.944089. eCollection 2022.
本文引用的文献
1
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer.
Genes Dev. 2021 Oct 1;35(19-20):1327-1332. doi: 10.1101/gad.348787.121. Epub 2021 Sep 16.
2
Stopping the beating heart of cancer: KRAS reviewed.
Curr Opin Struct Biol. 2021 Dec;71:136-147. doi: 10.1016/j.sbi.2021.06.013. Epub 2021 Jul 22.
3
Cancer Statistics, 2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
4
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer.
Cancer Discov. 2020 Jul;10(7):1058-1077. doi: 10.1158/2159-8290.CD-19-0597. Epub 2020 Apr 27.
5
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer.
Cell. 2019 Nov 14;179(5):1239. doi: 10.1016/j.cell.2019.10.037.
6
USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation.
Genes Dev. 2019 Oct 1;33(19-20):1361-1366. doi: 10.1101/gad.326314.119. Epub 2019 Sep 5.
7
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a031435. doi: 10.1101/cshperspect.a031435.
8
MARK3-mediated phosphorylation of ARHGEF2 couples microtubules to the actin cytoskeleton to establish cell polarity.
Sci Signal. 2017 Oct 31;10(503):eaan3286. doi: 10.1126/scisignal.aan3286.
9
Ubiquitin specific protease 21 is dispensable for normal development, hematopoiesis and lymphocyte differentiation.
PLoS One. 2015 Feb 13;10(2):e0117304. doi: 10.1371/journal.pone.0117304. eCollection 2015.
10
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.
Cell. 2012 Apr 27;149(3):656-70. doi: 10.1016/j.cell.2012.01.058.
Zotero 插件